Elevation of Eosinophil Proportion After Pembrolizumab Increases the Risk of Immune-Related Adverse Events in Patients With Bladder Cancer.
Rising white blood cell types after cancer immunotherapy predict serious side effects, enabling preventive clinical monitoring.
This Cancer Medicine multicenter retrospective cohort demonstrates that rising eosinophil proportion after pembrolizumab initiation in bladder cancer predicts subsequent immune-related adverse events. The finding leverages a routine CBC parameter for irAE risk stratification, directly applicable to clinical monitoring protocols for pembrolizumab-treated patients.
What the study was
- Study design
- Multicenter retrospective cohort study
- Population
- Bladder cancer patients treated with pembrolizumab at multiple Japanese centers
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Cancer medicine
Why it surfaced
Cancer Medicine multicenter study; CBC eosinophil as pembrolizumab irAE predictor is near-term implementable in immunotherapy monitoring programs.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.